| Rank |
Status |
Study |
| 1 |
Recruiting
|
The Use of Methadone in Newborn Infants
| Conditions: |
Premature Birth of Newborn; Critically Ill |
| Intervention: |
Drug: Methadone |
| Outcome Measures: |
Methadone PK and EDDP; DNA |
|
| 2 |
Recruiting
|
Methadone in Pediatric Anesthesiology II
| Condition: |
Pain |
| Interventions: |
Drug: Group 1- 0.4mg/kg IV Methadone HCl; Drug: Group 2 - 0.5mg/kg IV methadon HCI; Other: Group 3 - control no Methadone |
| Outcome Measures: |
Morphine consumption; Pain scores; Methadone clearance |
|
| 3 |
Recruiting
|
CYP2B6 Polymorphisms in Methadone
| Condition: |
Healthy Volunteers |
| Interventions: |
Drug: racemic Methadone HC1; Drug: Oral deuterated racemic Methadone HCl, |
| Outcome Measures: |
The effects of Methadone on healthy volunteers; Methadone and bupropion concentration; Methadone and bupropion clearance from the body; Oral Methadone and bupropion absorption; Influence of CYP2B6*6 hetero or homozyge genotype on the above primary and secondary outcomes |
|
| 4 |
Unknown †
|
Compare Methadone Combined With N-Acetyl-Cysteine (NAC) and Methadone Alone for Opioids Astaining
| Condition: |
Opioids Use |
| Interventions: |
Drug: Methadone; NAC; Drug: Methadone |
| Outcome Measure: |
|
|
| 5 |
Recruiting
|
Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?
| Conditions: |
Pain; Cancer of Head and Neck |
| Interventions: |
Drug: fentanyl; Drug: Methadone |
| Outcome Measures: |
significant pain relief (reduction of Numeric Rating Scale (NRS) of 50%); time to achieve significant pain relief; side-effect profile |
|
| 6 |
Recruiting
|
Methadone vs Magnesium in Spinal Fusion
| Condition: |
Idiopathic Scoliosis |
| Interventions: |
Drug: Methadone hydrochloride; Drug: Magnesium Sulfate; Drug: Remifentanil |
| Outcome Measures: |
Intra- and Post-operative Pain Relief; Intra-operative parameters |
|
| 7 |
Not yet recruiting
|
Drug Interaction & Methadone & Buprenorphine
| Condition: |
Hepatitis C |
| Interventions: |
Drug: Methadone; Drug: DCV 3DAA FDC; Drug: BMS-791325; Drug: Buprenorphine; Drug: Naloxone |
| Outcome Measures: |
Maximum observed concentration (Cmax) of R-Methadone for Part 1; Area under the concentration-time curve in one dosing interval (AUC(TAU)) of R-Methadone for Part 1; Cmax of Buprenorphine and Norbuprenorphine for Part 2; AUC(TAU) of Buprenorphine and Norbuprenorphine for Part 2; Cmax of S-Methadone and Total Methadone for Part 1; AUC(TAU) of S-Methadone and Total Methadone for Part 1; Concentration at 24 hours (C24) of S-Methadone, Total Methadone and R-Methadone for Part 1; Time of maximum observed concentration (Tmax) of S-Methadone, Total Methadone and R-Methadone for Part 1; C24 of Buprenorphine and Norbuprenorphine for Part 2; Tmax of Buprenorphine and Norbuprenorphine for Part 2; Ratio of metabolite AUC(TAU) to parent AUC(TAU) (MR_AUC(TAU)) of Norbuprenorphine to Buprenorphine; Cmax of of Daclatasvir (DCV) , Asunaprevir (ASV) , BMS-791325, and BMS-794712; AUC(TAU) of DCV, ASV, BMS-791325, and BMS-794712; Concentration at 12 hours (C12) of DCV, ASV, BMS-791325, and BMS-794712; Tmax of DCV, ASV, BMS-791325, and BMS-794712; MR_AUC(TAU) for BMS-794712 to BMS-791325; Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), death and AEs leading to discontinuation; Results of vital signs, Electrocardiograms (ECGs), Physical Examinations (PEs) and clinical labs; Scores of Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), Objective Opiate Withdrawal Scale (OOWS), and Opiate Overdose Assessment (OOA) |
|
| 8 |
Recruiting
|
Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal
| Condition: |
Opiate Withdrawal Syndrome |
| Intervention: |
Drug: Methadone |
| Outcome Measures: |
PK Parameters after multiple doses of enteral Methadone; PK of Methadone's primary metabolite EDDP; PK of R- and S-enantiomers of Methadone; Correlation between plasma and DBS samples; Correlation between plasma and scavenge samples; Influence of CYP3A4 and CYP3B6 genetic polymorphisms on Methadone PK; Methadone pharmacodynamics using the WAT-1; Adverse events |
|
| 9 |
Unknown †
|
Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone
| Conditions: |
Post Operative Pain; Hyperalgesia |
| Interventions: |
Drug: ketamine infusion; Drug: Methadone PCA |
| Outcome Measures: |
the extent of hyperalgesia area proximal to surgical wound; pain intensity; opioids related adverse events |
|
| 10 |
Unknown †
|
Methadone Versus Morphine for Orthopedic Surgery Patients
| Conditions: |
Fracture; Pain, Postoperative |
| Interventions: |
Drug: Methadone; Drug: Morphine |
| Outcome Measures: |
Opioid consumption during the 48 hours after surgery; Time to initial dose of rescue analgesic; Overall rescue analgesic; Side effects with special attention paid to respiratory rate and possible respiratory depression, and PONV; Overall satisfaction of the patient with the analgesic graded on a scale of 1-5 |
|
| 11 |
Recruiting
|
Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.
| Condition: |
Pain Related to Cancer |
| Intervention: |
Drug: Methadone |
| Outcome Measure: |
Binary main criterion based on success/failure rate related to Methadone switch on Day 4. |
|
| 12 |
Unknown †
|
Efficacy of Drug and Risk Counseling Among Methadone Patients in Jakarta, Indonesia
| Conditions: |
HIV Risk Behaviors; Heroin Injection; Retention in Methadone Treatment |
| Interventions: |
Behavioral: Behavioral Drug and Risk Counseling (BDRC); Behavioral: Methadone maintenance treatment |
| Outcome Measures: |
Injection drug use; retention in Methadone treatment |
|
| 13 |
Unknown †
|
Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone
| Condition: |
Substance-Related Disorders |
| Interventions: |
Drug: midazolam(drug), digoxin (drug); Drug: Bupropion (drug); Drug: Methadone (drug) |
| Outcome Measures: |
Explore if there is a correlation between the areas of the concentration curves of probe substrates for CYP3A4 and/or CYP2B6 and Pgp and the area of the concentration curve of Methadone.; LC-MS assays will be developed to analyze the plasma content of the probe substrates, Methadone and their metabolites. Specifically, midazolam, 1-OH midazolam, bupropion, t-butyl-hydroxy bupropion, digoxin, Methadone, and EDDP (a Methadone metabolite).; Isolate and bank the DNA of the subjects for future genotyping of variant alleles that will be identified in this study to be important in Methadone pharmacokinetics. |
|
| 14 |
Recruiting
|
Efficacy Methadone for Management Postoperative Pain After the Use of Anesthesia Intravenous in Laparoscopic Cholecystectomy
| Condition: |
Pain, Postoperative |
| Interventions: |
Drug: Morphine; Drug: Methadone; Drug: TIVA |
| Outcome Measures: |
Difference in milligrams of morphine used as rescue analgesia; Difference in pain scores, using the Numeric Rating Scale |
|
| 15 |
Not yet recruiting
|
Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients
| Conditions: |
Cigarette Smoking; Methadone Maintenance |
| Interventions: |
Drug: Nicotine Nasal Spray; Drug: Varenicline; Drug: Placebo Nasal Spray; Drug: Placebo Varenicline |
| Outcome Measures: |
Proportion of daily cigarettes smoked in the 4 hours after receiving Methadone dose; Cigarettes per day; Carbon monoxide level |
|
| 16 |
Recruiting
|
Pupillometry and Pain Thresholds Patients Substituted by Methadone and Buprenorphine
| Conditions: |
Opiate Dependent; Previous Illicit Drug Use |
| Intervention: |
Drug: Buprenorphine and Methadone Hydrochloride |
| Outcome Measures: |
Measurement of the pupil diameter; - The mechanical punctuate pain threshold as measured by Electronical Von Frey; - The mechanical pressure pain threshold measured by Algometer on the tibial bone; - The pupil diameter measured in scotopic .conditions (via infrared camera) at the hypothetical peak effect of either Methadone or buprenorphine.; - The pupil diameter measured in photopic conditions (via infrared camera) at the hypothetical residual effect of either Methadone or buprenorphine |
|
| 17 |
Recruiting
|
Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
| Condition: |
Low Back Pain |
| Interventions: |
Drug: Methadone; Drug: Buprenorphine/naloxone |
| Outcome Measures: |
Analgesia; Illicit drug use; Cravings; Functioning; Depression; Treatment retention |
|
| 18 |
Recruiting
|
Conversion From Parenteral to Oral Methadone.
| Condition: |
Pain |
| Interventions: |
Drug: Parenteral /oral Methadone ratio 1:2; Drug: Parenteral /oral Methadone ratio 1:1.2 |
| Outcome Measures: |
Proportion of intoxicated patients in each groups; Parenteral/oral MTD final ratio in patients considered as "failure" |
|
| 19 |
Recruiting
|
Methadone in Pediatric and Adult Sickle Cell Patients
| Condition: |
Sickle Cell Disease |
| Interventions: |
Drug: Morphine; Drug: Methadone |
| Outcome Measures: |
To determine the pharmacokinetics of Methadone in children and adults with Sickle Cell disease experiencing a VOE.; Pain |
|
| 20 |
Unknown †
|
Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain
| Conditions: |
Cancer; Pain; Palliative Care |
| Intervention: |
Drug: Methadone plus Acetaminophen or Placebo |
| Outcome Measures: |
Pain intensity and time to equianalgesic effect; Degree of nausea, vomiting, obstipation, xerostomia and drowsiness |
|
